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Abstract
Background: Poor platelet inhibition by aspirin or clopidogrel has been associated with adverse outcomes in patients 
with cardiovascular diseases. A reliable and facile assay to measure platelet inhibition after treatment with aspirin and a 
P2Y12 antagonist is lacking. Multiple electrode aggregometry (MEA), which is being increasingly used in clinical studies, 
is sensitive to platelet inhibition by aspirin and clopidogrel, but a critical evaluation of MEA monitoring of dual anti-
platelet therapy with aspirin and P2Y12 antagonists is missing.
Design and Methods: By performing in vitro and ex vivo experiments, we evaluated in healthy subjects the feasibility 
of using MEA to monitor platelet inhibition of P2Y12 antagonists (clopidogrel in vivo, cangrelor in vitro) and aspirin (100 
mg per day in vivo, and 1 mM or 5.4 mM in vitro) alone, and in combination. Statistical analyses were performed by the 
Mann-Whitney rank sum test, student' t-test, analysis of variance followed by the Holm-Sidak test, where appropriate.
Results: ADP-induced platelet aggregation in hirudin-anticoagulated blood was inhibited by 99.3 ± 1.4% by in vitro 
addition of cangrelor (100 nM; p < 0.001) and by 64 ± 35% by oral clopidogrel (600 mg) intake (p < 0.05; values are 
means ± SD). Pre-incubation of blood with aspirin (1 mM) or oral aspirin intake (100 mg/day for 1 week) inhibited 
arachidonic acid (AA)-stimulated aggregation >95% and 100 ± 3.2%, respectively (p < 0.01). Aspirin did not influence 
ADP-induced platelet aggregation, either in vitro or ex vivo. Oral intake of clopidogrel did not significantly reduce AA-
induced aggregation, but P2Y12 blockade by cangrelor (100 nM) in vitro diminished AA-stimulated aggregation by 53 ± 
26% (p < 0.01). A feasibility study in healthy volunteers showed that dual anti-platelet drug intake (aspirin and 
clopidogrel) could be selectively monitored by MEA.
Conclusions: Selective platelet inhibition by aspirin and P2Y12 antagonists alone and in combination can be rapidly 
measured by MEA. We suggest that dual anti-platelet therapy with these two types of anti-platelet drugs can be 
optimized individually by measuring platelet responsiveness to ADP and AA with MEA before and after drug intake.
Introduction
Ischemic cardio- and cerebrovascular events remain the 
leading causes of mortality worldwide, despite the increas-
ing use of angioplasty and pharmacological therapies: 
According to the 2008 WHO health statistics report [1], 
deaths from myocardial infarction and stroke are expected 
to rise from 21.9% of total global mortality in 2004 to 
26.3% in 2030. Treatment with aspirin (acetylsalicylic acid, 
ASA) of patients with cardiovascular disease reduces the 
risk of ischemic stroke, myocardial infarction, or death by 
about 25% [2]. Beside ASA, antagonists of the platelet 
ADP receptor P2Y12, such as clopidogrel and recently also 
prasugrel, have been shown to exert a protective effect in 
patients with cardio- and cerebrovascular diseases [3-5]. 
Moreover, dual anti-platelet therapy with ASA and a P2Y12 
antagonist (clopidogrel or prasugrel) has now been estab-
lished to prevent thrombotic complications of acute coro-
nary syndromes and percutaneous coronary interventions 
(PCI) [4-6].
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Despite the advances that have been made to date, many 
studies have shown significant variability of platelet reac-
tivity in patients treated with both ASA and clopidogrel 
[5,7]. A weak response to ASA [8,9] or clopidogrel [10-14], 
as determined by in vitro platelet function tests, has been 
significantly associated with adverse outcomes. In this con-
text, there is a need for a reliable assay for platelet function, 
since many of the platelet function tests used to monitor 
anti-platelet therapy are not optimal: they show large differ-
ences in monitoring anti-platelet drug intake [15]. A recent 
review concluded that commonly used laboratory tests do 
not reliably identify nonresponders to anti-platelet therapy 
[16]. Some researchers regard light transmission aggregom-
etry (LTA) of platelet-rich plasma (PRP) as the gold stan-
dard for platelet function testing. LTA is, however, a very 
poorly standardized technique [17]. LTA variations derive 
from different procedures for the preparation of PRP, the 
application of different devices, and different recording 
times and curve analysis algorithms (final aggregation/
maximal aggregation). Additional drawbacks are that LTA 
is laborious and time consuming and the separation of 
platelets from other blood cells is not physiological. More-
over, LTA lacks the required sensitivity to determine the 
effect of P2Y12 antagonists. Since signaling via P2Y1 
induces platelet shape change and reversible aggregation, 
and signaling through P2Y12 amplifies aggregation and ren-
ders it irreversible [7], P2Y12 receptor blockade only 
reduces, but does not completely inhibit, ADP-induced 
aggregation of PRP. Furthermore, LTA also lacks the speci-
ficity to measure the effect of P2Y12 antagonists in patients 
concomitantly taking ASA, since ASA can inhibit ADP-
induced aggregation of PRP [18].
Dual anti-platelet therapy with ASA plus a P2Y12 antago-
nist (clopidogrel or prasugrel) is increasingly used in 
patients with acute coronary syndromes undergoing PCI [4-
6]. There is a clinical need for a reliable test to measure 
dual platelet inhibition after ASA and P2Y12 antagonist 
treatment in order to optimize anti-platelet therapy in indi-
vidual patients. A relatively new system, which is becom-
ing increasingly popular in clinical studies, is multiple 
electrode aggregometry (MEA) [19]. This method, which is 
based on impedance aggregometry [20], allows the analysis 
of platelet aggregation in whole blood. It has been shown 
that MEA is sensitive to platelet inhibition by ASA [19,21] 
and clopidogrel [14,21], Recently, high ADP-induced plate-
let aggregation determined by MEA in patients treated with 
clopidogrel has been found to be a significant risk factor for 
stent thrombosis with a hazard ratio of 9.4 [22].
In the present study, we evaluated the use of MEA for mon-
itoring dual anti-platelet therapy with ASA and a P2Y12 
antagonist. In the first part of the study, we conducted an in 
vitro investigation of important possible confounding fac-
tors, such as the influence of P2Y12 inhibition with cangre-
lor on arachidonic acid (AA)-induced aggregation and the 
effect of ASA on ADP-induced aggregation. In the second 
part of the investigation, we performed a feasibility study of 
MEA monitoring of platelet inhibition after oral intake of 
ASA and clopidogrel, alone and in combination, in healthy 
volunteers.
Design and Methods
Reagents and chemicals
ASA, ADP, apyrase (grade VII), AA and the P2Y1 receptor 
antagonist MRS2179 (N6-methyl-2'-deoxyadenosine-3',5'-
bisphosphate) were obtained from Sigma (Taufkirchen, 
Germany). ADPtest, ASPItest (contains AA) and ASA con-
trol used in the ex vivo study were purchased from Dyna-
byte (Munich, Germany). Recombinant hirudin 
(Refludan®) was purchased from Schering (Berlin, Ger-
many). The P2Y12 receptor antagonist cangrelor (AR-
C69931MX;N6-2-(methylthioethyl)-2-(3,3,3-trifluoropro-
pylthio)-β, γ-dichloromethylene ATP) was generously pro-
vided by Astra-Zeneca R&D Charnwood (Loughborough, 
UK). Clopidogrel was obtained from Bristol-Myers Squibb 
Pharma EEIG (Iscover® 300 mg, Uxbridge, UK), and ASA 
from Bayer Vital GmbH (ASA® 100 mg, Leverkusen, Ger-
many). All other chemicals were obtained from Merck 
(Darmstadt, Germany).
Blood collection and study design
For the in vitro experiments, blood samples (10 - 50 ml) 
were collected following written informed consent from 18 
healthy volunteers, who had not taken any anti-platelet 
drugs for at least 14 days prior to the experiments. The col-
lection of blood samples from healthy volunteers was 
approved by the Ethics Committee of the University of 
Munich. The blood samples were drawn by venipuncture 
using a 19-gauge needle into plastic syringes containing 1/
10 volume recombinant hirudin (final concentration in 
blood: 13 μg/ml) dissolved in 20 mM HEPES, 138 mM 
NaCl, 1 mM MgCl2.6 H2O, and 0.36 mM NaH2PO4, pH 
7.4. The first 3 ml of blood were discarded. For the in-vitro 
experiments, different concentrations of cangrelor or 
MRS2179 were added 1 min before ADP or AA. ASA was 
dissolved in hirudin-containing buffer solution and drawn 
together with the anticoagulant into a syringe to obtain a 
final concentration of 1 mM ASA in the collected blood 
sample. Platelet aggregation was studied on a Multiplate® 
analyzer (Dynabyte; Munich, Germany) 45 to 180 min fol-
lowing sampling.
The ex vivo study of the effects of oral intake of ASA, 
clopidogrel or a combination of the two drugs was carried 
out by and on five healthy medical doctors, in accordance 
with the principles of the Helsinki Declaration. All subjects 
denied taking any medication affecting platelet function in 
the two weeks prior to this study. Blood samples were col-Penz et al. Thrombosis Journal 2010, 8:9
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lected by venipuncture using a 21-gauge needle into plastic 
syringes pre-filled with recombinant hirudin (final concen-
tration in blood: 25 μg/ml) and analyzed by MEA 30 to 120 
min following sampling. The first 3 ml of blood were dis-
carded. Blood was taken on day 0 (baseline 1), on day 7 
after daily intake of ASA 100 mg for 7 days, on day 7 plus 
4 h after the additional intake of 600 mg clopidogrel, after a 
washout period of 35 days (baseline 2), and on day 35 plus 
4 h after 600 mg clopidogrel intake (Figure 1). Each blood 
sample from all the study participants was exposed to one 
of the following treatments: saline (spontaneous aggrega-
tion), ADP 6.5 μM (ADPtest), cangrelor 100 nM plus ADP 
6.5 μM, AA 0.6 mM (ASPItest), cangrelor 100 nM plus AA 
0.6 mM, and ASA 5.4 mM (ASA control; standard concen-
tration recommended by the manufacturer) plus AA 0.6 
mM.
Platelet aggregation measurements
Platelet aggregation was measured for 5 min in diluted 
whole blood by impedance aggregometry using a Multi-
plate® analyzer, as described previously [19]. Briefly, for 
the in vitro studies a 1:1 mixture of preheated saline and 
whole hirudin-anticoagulated blood without ASA or with 1 
mM ASA was stirred for 3 min at 37°C in single-use Multi-
plate®-test cells. In some experiments, the saline portion of 
the sample was supplemented with apyrase to inactivate 
ADP (10 U/ml) or with increasing concentrations of 
MRS2179 or cangrelor. After the incubation period, platelet 
aggregation was induced by adding ADP or AA, and mea-
surements were started.
For the ex vivo studies, samples of 320 μl of saline (pre-
warmed to 37°C) plus 300 μl of hirudin-anticoagulated 
blood were placed in single-use Multiplate® test cells and 
stirred for 3 min at 37°C. In some of these experiments, the 
saline fraction contained cangrelor (100 nM) or ASA (5.4 
mM; ASA control). After 3 min of incubation, platelet 
aggregation was induced by adding either ADP (6.5 μM; 
ADPtest) or AA (0.6 mM; ASPItest), and measurements 
were begun. All measurements were performed in duplicate 
(Figure 1). The area under the curve (AUC) was used to 
express platelet aggregation in arbitrary aggregation units 
(AU) multiplied by the recorded time in minutes 
(AU*min).
Statistical analysis
Results are given as means ± SD of the number of samples 
comprising blood of different healthy donors. All platelet 
function tests were run in duplicate, and means of duplicate 
determinations were used for figures and statistics. In vitro 
stimulation data were always compared to unstimulated 
control data by the Mann-Whitney rank sum test or in case 
of normality and equality of variance by Student's t-test.
Results of ex vivo platelet tests obtained after the various 
treatments were first analyzed for each stimulus for normal-
ity by the Kolmogoroff-Smirnoff test and of equality 
according to Cochran. Then the effect of the various treat-
ments was tested by analysis of variance for overall signifi-
cance. Post-hoc pair comparisons between treatment groups 
were then made by the Holm-Sidak-test. For all statistical 
analyses, a value of p < 0.05 was considered significant.
Results
Effect of P2Y1 and P2Y12 inhibition on ADP-induced 
aggregation in MEA
Dose-response curves showed concentration-dependent 
inhibition of ADP-induced platelet aggregation in hirudin-
anticoagulated blood by the ADP receptor P2Y1 antagonist 
MRS2179 and by the ADP receptor P2Y12 antagonist can-
grelor (Figure 2). ADP-stimulated platelet aggregation was 
inhibited by >90% by maximal concentrations of MRS2179 
and cangrelor. Cangrelor (100 nM) reduced ADP (6.5 μM)-
induced aggregation of platelets obtained from different 
blood donors from 530 ± 122 AU*min to 60 ± 33 AU*min 
(spontaneous aggregation was 57 ± 41 AU*min; n = 5). 
Inhibition by cangrelor in vitro was therefore 99.3 ± 1.4% 
(p < 0.001). The effective inhibitory concentrations (IC50) 
on platelet aggregation induced by 5 μM ADP were 1.5 μM 
for MRS2179 and 3 nM for cangrelor.
Effect of ASA on ADP- and AA- induced platelet 
aggregation
Pre-treatment of blood with ASA (1 mM) had no effect on 
platelet aggregation stimulated by ADP (0.5-5 μM) (Figure 
3A) but significantly reduced AA-stimulated aggregation 
by > 95% in all individuals tested (n = 13; p < 0.05; Figure 
3B). A higher concentration of ASA (5.4 mM) reduced AA 
(0.6 mM)-induced aggregation of platelets to levels that fell 
below those of spontaneous aggregation: the respective 
aggregation values were: for AA 603 ± 83 AU*min; for 
ASA+AA 18 ± 21 AU*min (spontaneous aggregation 57 ± 
41 AU*min; p < 0.001). The two lower concentrations of 
AA (0.1 and 0.3 mM) did not induce in each individual an 
aggregation response. Furthermore, for some donors, the 
aggregation value for the highest AA concentration, 1.2 
mM, was lower than that for 0.6 mM AA.
Effect of apyrase and cangrelor on AA- induced platelet 
aggregation
AA (0.6 mM)-stimulated platelet aggregation was reduced 
to a similar degree by cangrelor (100 nM) and by the ADP 
scavenger enzyme apyrase (10 U/ml), i.e., by 53 ± 26% and 
64 ± 29%, respectively (Figure 4). However, pre-treatment 
of blood with ASA (1 mM) almost completely inhibited 
AA-mediated platelet aggregation (Figure 4).
Also in the ex vivo study (see below), the reduction of AA-
stimulated platelet aggregation by cangrelor (100 nM) in 
vitro was assayed. At days 0 and 35 (baselines 1 and 2, 
respectively), cangrelor reduced AA-induced aggregation Penz et al. Thrombosis Journal 2010, 8:9
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from 603 ± 83 AU*min and 636 ± 121 AU*min to 297 ± 
121 AU*min and 307 ± 109 AU*min, respectively (n = 5; p 
< 0.01). This difference amounts to a reduction by cangre-
lor of AA-induced aggregation of 51% and 52%, respec-
tively.
Platelet inhibition by ASA, clopidogrel and clopidogrel plus 
ASA ex vivo
Based on the above in vitro results, we performed a feasibil-
ity study to evaluate whether MEA can be used to selec-
tively monitor platelet inhibition after oral intake of ASA 
(100 mg/day for one week) and clopidogrel (a single load-
ing dose of 600 mg) alone and in combination (Figure 1; 
Methods). Figure 5 summarizes the results of MEA mea-
surements for five healthy individuals before (baseline 1) 
and after oral intake of the anti-platelet drugs alone or in 
combination, and after a washout period of 4 weeks (base-
line 2). Intra-individual ADP- and AA-stimulated aggrega-
tion values did not differ significantly at the two baseline 
measurements: The mean values of ADP-induced aggrega-
tion were 530 ± 123 AU*min and 490 ± 81 AU*min at 
baselines 1 and 2, respectively; the mean measured values 
of AA-induced aggregation were 603 ± 83 AU*min and 
637 ± 122 at baselines 1 and 2, respectively (means ± SD, n 
= 5).
Intake of a low dose of ASA for one week resulted in com-
plete inhibition of AA (0.6 mM)-stimulated aggregation in 
all five individuals (100 ± 3.2%; p < 0.01). Subsequent 
addition of ASA to the blood samples in vitro lowered the 
aggregation response in some individuals to values that fell 
below the levels of spontaneous aggregation. ASA intake 
did not significantly inhibit ADP-induced platelet aggrega-
tion in any of the blood donors (Figure 5).
Platelet responsiveness to clopidogrel, determined 4 h after 
a single 600 mg loading dose, varied in the five volunteers 
(Figure 5). ADP-induced aggregation was inhibited by 
<10% in individual 3, and by 100%, 50%, 75% and 85% in 
individuals 1, 2, 4 and 5, respectively (mean ± SD: 64 ± 
35% inhibition; p < 0.05). The in vitro addition of cangrelor 
reduced AA-induced aggregation by 51% (range: 23 to 
77%; p < 0.01; see above), whereas ASA intake (alone or in 
combination with clopidogrel) completely inhibited AA-
induced aggregation in all individuals (p < 0.01) (Figure 5).
Clopidogrel intake did not inhibit AA-induced aggregation 
(Figure 5), except in one volunteer. In this individual, 
which showed a complete inhibition of ADP-induced 
aggregation by clopidogrel, AA-stimulated platelet aggre-
gation by clopidogrel was reduced to a degree (by 58%) 
similar to that seen after in vitro incubation with cangrelor 
(by 65%).
Discussion
Our results indicate that in MEA ADP-induced aggregation 
is not influenced by ASA and is therefore specific for ADP 
Figure 1 Design of the ex vivo study investigating the effects of oral intake of ASA, clopidogrel or a combination of both drugs on platelet 
aggregation measured by MEA.
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receptor blockade (Figures 3 and 5). As shown in Figure 2, 
ADP-stimulated aggregation was completely inhibited by 
either P2Y12 or P2Y1 blockade. The assay presented in this 
paper is thus P2Y12 receptor antagonist selective, on condi-
tion that the patient takes drugs that inhibit only the platelet 
P2Y12 receptor (e. g., clopidogrel, prasugrel, or the novel 
oral reversible P2Y12 antagonist AZD6140 [18]) and not the 
P2Y1 receptor. The selectivity of the assay for P2Y12 recep-
tor antagonists is based on the findings that: (a) ADP-
induced platelet aggregation of hirudin-anticoagulated 
whole blood is not inhibited by ASA, even at very high 
concentrations (in contrast to ADP-stimulated platelet 
aggregation in citrated PRP or suspensions of washed 
human platelets [18]), and (b) that P2Y12 receptor activation 
is required for ADP-induced aggregation in blood. The 
maximal inhibitory concentration (100 nM) of the P2Y12 
receptor antagonist cangrelor completely blocked ADP-
mediated aggregation, thereby confirming our previous 
observations using single-platelet counting [23]. Further-
more, it has previously been shown in patients with acute 
coronary syndrome that intravenous administration of high 
concentrations of cangrelor could completely inhibit ADP-
induced platelet aggregation, as measured ex vivo in blood 
[24]. It should be noted here that the mechanism of ADP-
induced platelet aggregation in whole blood seems to be 
different from that in PRP and in suspensions of washed 
human platelets. In PRP and washed platelet suspensions, 
platelet aggregation is initiated by P2Y1 activation and only 
amplified by the activation of P2Y12 [25]. It appears that for 
ADP-induced platelet aggregation in whole blood there is a 
strict requirement for concomitant (or sequential) activation 
of both P2Y receptors and their corresponding signaling 
pathways.
The most specific assay measuring the function of the 
clopidogrel target, the P2Y12 receptor, is the determination 
of the state of vasodilator-stimulated phosphoprotein 
(VASP) phosphorylation by flow cytometry [18,26,27]. 
This method measures a biochemical parameter, i.e., the 
decrease of ADP-induced Gi-mediated dephosphorylation 
after prior stimulation of Gs-mediated phosphorylation with 
prostaglandin E1 (PGE1). However, the VASP-based assay 
- being far more complex than the MEA determination - has 
Figure 2 Inhibition of ADP (5 μM)-induced platelet aggregation 
by cangrelor (empty squares) and MRS2179 (filled diamonds). 
Data are means ± SD (n = 5). **p < 0.001 for cangrelor/MRS2179 versus 
control.
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some inherent disadvantages: it involves a number of steps 
(fixation of blood, detergent lysis of platelets) and a number 
of reagents (PGE1, phosphorylation-site specific VASP 
antibody), and moreover FACS analysis requires sophisti-
cated equipment and an experienced technician. Thus, we 
conclude that the measurement of the clopidogrel response 
can be more easily performed by MEA than by measuring 
VASP phosphorylation.
The bell-shaped dose-response curve of AA-induced plate-
let aggregation in blood confirms previous studies using 
washed platelet suspensions [28]. Inhibition of platelet 
aggregation after exposure to high concentrations of AA is 
probably due to enhanced formation of platelet inhibitory 
12-lipoxygenase metabolites [29].
In the present study, we found that AA-stimulated aggrega-
tion of blood was dependent on extracellular ADP and 
P2Y12 receptor activation. The ADP scavenger enzyme 
apyrase and cangrelor (100 nM) reduced AA-stimulated 
platelet aggregation to similar degrees. The inhibition of 
AA-induced aggregation by P2Y12 blockade may be 
explained by the following reasoning: AA-stimulated 
aggregation of washed platelets and PRP is known to be 
partially mediated by thromboxane A2-induced release of 
ADP [29]. The situation for AA-stimulated aggregation of 
platelets in blood might be similar, i.e., thromboxane A2-
induced secretion of ADP could reinforce platelet aggrega-
tion by activation of P2Y12.
In all individuals participating in the ex vivo study, oral 
intake of ASA inhibited completely AA-induced aggrega-
tion. In contrast, in the small study of healthy volunteers, 
AA-induced aggregation by oral clopidogrel intake was not 
significantly reduced. However, we did observe in individ-
ual volunteers that after oral clopidogrel intake AA-induced 
aggregation was reduced when ADP-induced aggregation 
was completely blocked (data not shown). These observa-
tions are in line with our in vitro findings of cangrelor on 
Figure 5 Platelet inhibition by ASA, clopidogrel and clopidogrel plus ASA ex vivo. Platelet aggregation as determined by MEA before drug in-
take (baseline 1; black bars), after oral intake of ASA (100 mg/d for 7 days; white vertically striped grey bars), ASA (100 mg/d for 7 days) plus clopidogrel 
(600 mg for 4 h; white bars), after 4 weeks of washout (baseline 2; white horizontally striped dark grey bars), and clopidogrel (600 mg for 4 h; grey bars). 
Blood from five healthy volunteers was exposed to saline (spontaneous aggregation), ADP (6.5 μM), cangrelor (100 nM) + ADP (6.5 μM), AA (0.6 mM), 
cangrelor (100 nM) + AA (0.6 mM), ASA in vitro (5.4 mM) + AA (0.6 mM). Data are means ± SD (n = 5). The effects of various treatments (after oral intake 
of ASA, clopidogrel, or both) on platelet aggregation challenged with each stimulus was first tested with overall analysis of variance (n.s. non-signifi-
cant; §§: p < 0.01; §§§: p < 0.001; on top of the bars) followed by pair comparisons of the individual treatments by the Holm-Sidak-Test, as indicated 
in brackets under the x-axis (* p < 0.05; ** p < 0.01).Penz et al. Thrombosis Journal 2010, 8:9
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AA-stimulated aggregation (see above). In the light of our 
results, we predict that in patients taking ASA and treated 
with potent ADP receptor antagonists such as cangrelor or 
prasugrel, inhibition of AA-induced aggregation by >95% 
will indicate that the platelets are also inhibited by ASA. It 
would be important to validate such an assumption by 
future studies in a large cohort of cardiovascular patients.
In summary, we have shown (a) that ADP-induced aggrega-
tion in MEA is not influenced by ASA both in vitro and ex 
vivo; (b) that P2Y12 inhibition alone is sufficient to block 
ADP-induced aggregation in MEA, making this method 
sufficiently sensitive to monitor the intake of P2Y12 recep-
tor antagonists; (c) that a potent P2Y12 blockade reduces 
AA-induced aggregation in MEA both in vitro and ex vivo; 
and (d) that ASA inhibited by >95% AA-induced aggrega-
tion in MEA in vitro and ex vivo. We therefore conclude 
that it is possible to monitor rapidly (5 tests are completed 
in less than 10 min) and selectively platelet inhibition after 
intake of ASA and P2Y12 antagonists alone or in combina-
tion. In view of our promising findings, we suggest that 
anti-platelet therapy with these two types of anti-platelet 
drugs can be optimized individually by measuring platelet 
responsiveness with MEA before and after drug intake.
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